Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 1(4)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04684121Phase 2Withdrawn

Study of the Efficacy and Safety of Granexin® Gel to Improve Burn Wound Healing

Role: lead

NCT04331080Phase 2Completed

A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery

Role: lead

NCT05031806Phase 1Completed

Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease

Role: lead

NCT04473859Phase 1Completed

Study to Evaluate the Safety of FSR Peptide Versus Placebo Following Punch Biopsy

Role: lead

NCT02667327Phase 3Terminated

A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer

Role: lead

NCT02652572Phase 1Completed

Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers

Role: lead

NCT02652754Phase 1Completed

Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers

Role: lead

All 7 trials loaded